Physician profile
Ajay Anand
NPI 1164400230
$1,949.01
in general payments reported to CMS, 2019-2025
22 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.62 · 2020: $117 · 2021: $374 · 2022: $368 · 2023: $210 · 2024: $304 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $426.84 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $226.34 | 2019-2024 | Tresiba, Rybelsus, Ozempic |
| Lilly USA, LLC | $215.64 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $176.73 | 2020-2024 | |
| Amgen INC. | $169.74 | 2019-2022 | |
| Abiomed | $144.36 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.33 | 2021-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $80.06 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $62.12 | 2023-2025 | Farxiga, Brilinta, Breztri |
| Abbvie INC. | $59.78 | 2021-2022 | |
| Amarin Pharma, INC. | $42.52 | 2021 | |
| Alkermes, INC. | $29.28 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $28.58 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $26.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.15 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $23.12 | 2024 | Skyclarys |
| Abbott Laboratories | $16.75 | 2020 | |
| Pfizer INC. | $16.61 | 2021 | |
| Philips North America LLC | $16.31 | 2024 | (Ck4) Mcot |
| Averitas Pharma INC. | $15.11 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $14.55 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.65 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.